Cargando…

Variant-specific deleterious mutations in the SARS-CoV-2 genome reveal immune responses and potentials for prophylactic vaccine development

Introduction: Coronavirus disease 2019 (COVID-19), caused by SARS-CoV-2, has had a disastrous effect worldwide during the previous three years due to widespread infections with SARS-CoV-2 and its emerging variations. More than 674 million confirmed cases and over 6.7 million deaths have been attribu...

Descripción completa

Detalles Bibliográficos
Autores principales: Islam, Md. Aminul, Shahi, Shatila, Marzan, Abdullah Al, Amin, Mohammad Ruhul, Hasan, Mohammad Nayeem, Hoque, M. Nazmul, Ghosh, Ajit, Barua, Abanti, Khan, Abbas, Dhama, Kuldeep, Chakraborty, Chiranjib, Bhattacharya, Prosun, Wei, Dong-Qing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9941545/
https://www.ncbi.nlm.nih.gov/pubmed/36825152
http://dx.doi.org/10.3389/fphar.2023.1090717
_version_ 1784891307359993856
author Islam, Md. Aminul
Shahi, Shatila
Marzan, Abdullah Al
Amin, Mohammad Ruhul
Hasan, Mohammad Nayeem
Hoque, M. Nazmul
Ghosh, Ajit
Barua, Abanti
Khan, Abbas
Dhama, Kuldeep
Chakraborty, Chiranjib
Bhattacharya, Prosun
Wei, Dong-Qing
author_facet Islam, Md. Aminul
Shahi, Shatila
Marzan, Abdullah Al
Amin, Mohammad Ruhul
Hasan, Mohammad Nayeem
Hoque, M. Nazmul
Ghosh, Ajit
Barua, Abanti
Khan, Abbas
Dhama, Kuldeep
Chakraborty, Chiranjib
Bhattacharya, Prosun
Wei, Dong-Qing
author_sort Islam, Md. Aminul
collection PubMed
description Introduction: Coronavirus disease 2019 (COVID-19), caused by SARS-CoV-2, has had a disastrous effect worldwide during the previous three years due to widespread infections with SARS-CoV-2 and its emerging variations. More than 674 million confirmed cases and over 6.7 million deaths have been attributed to successive waves of SARS-CoV-2 infections as of 29th January 2023. Similar to other RNA viruses, SARS-CoV-2 is more susceptible to genetic evolution and spontaneous mutations over time, resulting in the continual emergence of variants with distinct characteristics. Spontaneous mutations of SARS-CoV-2 variants increase its transmissibility, virulence, and disease severity and diminish the efficacy of therapeutics and vaccines, resulting in vaccine-breakthrough infections and re-infection, leading to high mortality and morbidity rates. Materials and methods: In this study, we evaluated 10,531 whole genome sequences of all reported variants globally through a computational approach to assess the spread and emergence of the mutations in the SARS-CoV-2 genome. The available data sources of NextCladeCLI 2.3.0 (https://clades.nextstrain.org/) and NextStrain (https://nextstrain.org/) were searched for tracking SARS-CoV-2 mutations, analysed using the PROVEAN, Polyphen-2, and Predict SNP mutational analysis tools and validated by Machine Learning models. Result: Compared to the Wuhan-Hu-1 reference strain NC 045512.2, genome-wide annotations showed 16,954 mutations in the SARS-CoV-2 genome. We determined that the Omicron variant had 6,307 mutations (retrieved sequence:1947), including 67.8% unique mutations, more than any other variant evaluated in this study. The spike protein of the Omicron variant harboured 876 mutations, including 443 deleterious mutations. Among these deleterious mutations, 187 were common and 256 were unique non-synonymous mutations. In contrast, after analysing 1,884 sequences of the Delta variant, we discovered 4,468 mutations, of which 66% were unique, and not previously reported in other variants. Mutations affecting spike proteins are mostly found in RBD regions for Omicron, whereas most of the Delta variant mutations drawn to focus on amino acid regions ranging from 911 to 924 in the context of epitope prediction (B cell & T cell) and mutational stability impact analysis protruding that Omicron is more transmissible. Discussion: The pathogenesis of the Omicron variant could be prevented if the deleterious and persistent unique immunosuppressive mutations can be targeted for vaccination or small-molecule inhibitor designing. Thus, our findings will help researchers monitor and track the continuously evolving nature of SARS-CoV-2 strains, the associated genetic variants, and their implications for developing effective control and prophylaxis strategies.
format Online
Article
Text
id pubmed-9941545
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-99415452023-02-22 Variant-specific deleterious mutations in the SARS-CoV-2 genome reveal immune responses and potentials for prophylactic vaccine development Islam, Md. Aminul Shahi, Shatila Marzan, Abdullah Al Amin, Mohammad Ruhul Hasan, Mohammad Nayeem Hoque, M. Nazmul Ghosh, Ajit Barua, Abanti Khan, Abbas Dhama, Kuldeep Chakraborty, Chiranjib Bhattacharya, Prosun Wei, Dong-Qing Front Pharmacol Pharmacology Introduction: Coronavirus disease 2019 (COVID-19), caused by SARS-CoV-2, has had a disastrous effect worldwide during the previous three years due to widespread infections with SARS-CoV-2 and its emerging variations. More than 674 million confirmed cases and over 6.7 million deaths have been attributed to successive waves of SARS-CoV-2 infections as of 29th January 2023. Similar to other RNA viruses, SARS-CoV-2 is more susceptible to genetic evolution and spontaneous mutations over time, resulting in the continual emergence of variants with distinct characteristics. Spontaneous mutations of SARS-CoV-2 variants increase its transmissibility, virulence, and disease severity and diminish the efficacy of therapeutics and vaccines, resulting in vaccine-breakthrough infections and re-infection, leading to high mortality and morbidity rates. Materials and methods: In this study, we evaluated 10,531 whole genome sequences of all reported variants globally through a computational approach to assess the spread and emergence of the mutations in the SARS-CoV-2 genome. The available data sources of NextCladeCLI 2.3.0 (https://clades.nextstrain.org/) and NextStrain (https://nextstrain.org/) were searched for tracking SARS-CoV-2 mutations, analysed using the PROVEAN, Polyphen-2, and Predict SNP mutational analysis tools and validated by Machine Learning models. Result: Compared to the Wuhan-Hu-1 reference strain NC 045512.2, genome-wide annotations showed 16,954 mutations in the SARS-CoV-2 genome. We determined that the Omicron variant had 6,307 mutations (retrieved sequence:1947), including 67.8% unique mutations, more than any other variant evaluated in this study. The spike protein of the Omicron variant harboured 876 mutations, including 443 deleterious mutations. Among these deleterious mutations, 187 were common and 256 were unique non-synonymous mutations. In contrast, after analysing 1,884 sequences of the Delta variant, we discovered 4,468 mutations, of which 66% were unique, and not previously reported in other variants. Mutations affecting spike proteins are mostly found in RBD regions for Omicron, whereas most of the Delta variant mutations drawn to focus on amino acid regions ranging from 911 to 924 in the context of epitope prediction (B cell & T cell) and mutational stability impact analysis protruding that Omicron is more transmissible. Discussion: The pathogenesis of the Omicron variant could be prevented if the deleterious and persistent unique immunosuppressive mutations can be targeted for vaccination or small-molecule inhibitor designing. Thus, our findings will help researchers monitor and track the continuously evolving nature of SARS-CoV-2 strains, the associated genetic variants, and their implications for developing effective control and prophylaxis strategies. Frontiers Media S.A. 2023-02-07 /pmc/articles/PMC9941545/ /pubmed/36825152 http://dx.doi.org/10.3389/fphar.2023.1090717 Text en Copyright © 2023 Islam, Shahi, Marzan, Amin, Hasan, Hoque, Ghosh, Barua, Khan, Dhama, Chakraborty, Bhattacharya and Wei. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Pharmacology
Islam, Md. Aminul
Shahi, Shatila
Marzan, Abdullah Al
Amin, Mohammad Ruhul
Hasan, Mohammad Nayeem
Hoque, M. Nazmul
Ghosh, Ajit
Barua, Abanti
Khan, Abbas
Dhama, Kuldeep
Chakraborty, Chiranjib
Bhattacharya, Prosun
Wei, Dong-Qing
Variant-specific deleterious mutations in the SARS-CoV-2 genome reveal immune responses and potentials for prophylactic vaccine development
title Variant-specific deleterious mutations in the SARS-CoV-2 genome reveal immune responses and potentials for prophylactic vaccine development
title_full Variant-specific deleterious mutations in the SARS-CoV-2 genome reveal immune responses and potentials for prophylactic vaccine development
title_fullStr Variant-specific deleterious mutations in the SARS-CoV-2 genome reveal immune responses and potentials for prophylactic vaccine development
title_full_unstemmed Variant-specific deleterious mutations in the SARS-CoV-2 genome reveal immune responses and potentials for prophylactic vaccine development
title_short Variant-specific deleterious mutations in the SARS-CoV-2 genome reveal immune responses and potentials for prophylactic vaccine development
title_sort variant-specific deleterious mutations in the sars-cov-2 genome reveal immune responses and potentials for prophylactic vaccine development
topic Pharmacology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9941545/
https://www.ncbi.nlm.nih.gov/pubmed/36825152
http://dx.doi.org/10.3389/fphar.2023.1090717
work_keys_str_mv AT islammdaminul variantspecificdeleteriousmutationsinthesarscov2genomerevealimmuneresponsesandpotentialsforprophylacticvaccinedevelopment
AT shahishatila variantspecificdeleteriousmutationsinthesarscov2genomerevealimmuneresponsesandpotentialsforprophylacticvaccinedevelopment
AT marzanabdullahal variantspecificdeleteriousmutationsinthesarscov2genomerevealimmuneresponsesandpotentialsforprophylacticvaccinedevelopment
AT aminmohammadruhul variantspecificdeleteriousmutationsinthesarscov2genomerevealimmuneresponsesandpotentialsforprophylacticvaccinedevelopment
AT hasanmohammadnayeem variantspecificdeleteriousmutationsinthesarscov2genomerevealimmuneresponsesandpotentialsforprophylacticvaccinedevelopment
AT hoquemnazmul variantspecificdeleteriousmutationsinthesarscov2genomerevealimmuneresponsesandpotentialsforprophylacticvaccinedevelopment
AT ghoshajit variantspecificdeleteriousmutationsinthesarscov2genomerevealimmuneresponsesandpotentialsforprophylacticvaccinedevelopment
AT baruaabanti variantspecificdeleteriousmutationsinthesarscov2genomerevealimmuneresponsesandpotentialsforprophylacticvaccinedevelopment
AT khanabbas variantspecificdeleteriousmutationsinthesarscov2genomerevealimmuneresponsesandpotentialsforprophylacticvaccinedevelopment
AT dhamakuldeep variantspecificdeleteriousmutationsinthesarscov2genomerevealimmuneresponsesandpotentialsforprophylacticvaccinedevelopment
AT chakrabortychiranjib variantspecificdeleteriousmutationsinthesarscov2genomerevealimmuneresponsesandpotentialsforprophylacticvaccinedevelopment
AT bhattacharyaprosun variantspecificdeleteriousmutationsinthesarscov2genomerevealimmuneresponsesandpotentialsforprophylacticvaccinedevelopment
AT weidongqing variantspecificdeleteriousmutationsinthesarscov2genomerevealimmuneresponsesandpotentialsforprophylacticvaccinedevelopment